Company / Shareholders' Equity
4D Molecular Therapeutics, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$510.6M
FY2025
5-year range
$231.3M / $510.6M
FY2021-FY2025
Trend
+65.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $231M to $511M over the past 2 years.
Based on SEC 10-K filings.
$511M in FY2025 with a 3-year CAGR of +17.0%.
Improved from $231M to $511M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +17.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +17.0%, indicating consistent growth.
- In FY2025, shareholders' equity increased 65.9% year-over-year.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $510.6M | +65.9% |
| FY2024 | $307.8M | +33.1% |
| FY2023 | $231.3M | -27.5% |
| FY2022 | $319.1M | +24.5% |
| FY2021 | $256.4M | +451.4% |
| FY2020 | -$73.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026